Stock Market Reviews

Read and share opinions on TERN (Terns Pharmaceuticals, Inc.) stock. Join MyTopStock.com to discover reviews, insights, and discussions from investors about this company's performance in the stock mar

Latest News

• Terns Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in London
  Nov 14, 2025
• Terns Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Corporate Updates
  Nov 10, 2025
• Terns Pharmaceuticals (TERN): Assessing Valuation Following Promising TERN-701 CML Trial Results and Analyst Upgrades
  Nov 6, 2025
• Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)
  Nov 4, 2025
• Terns Pharmaceuticals (TERN) Is Up 74.1% After Positive Phase 1 TERN-701 Data in CML Patients
  Nov 4, 2025
• Terns Announces Abstract with Positive Clinical Data for TERN-701 in Relapsed/Refractory CML Selected for Oral Presentation at 67th ASH Annual Meeting
  Nov 3, 2025
• Terns Pharmaceuticals Ends Obesity Program After TERN-601 Fails to Meet Phase 2 Trial Goals
  Oct 22, 2025
• Terns Pharmaceuticals Reports Topline 12-week Data from its Phase 2 Trial Evaluating Oral GLP-1 Receptor Agonist TERN-601 in Obesity
  Oct 21, 2025
• Terns Pharmaceuticals to Host an Educational Webinar on TERN-701 for Investors in Advance of Phase 1 Data Expected in Fourth Quarter 2025
  Aug 21, 2025
• Eli Lilly's Rare Weight Loss Data Miss Could Benefit Competitors
  Aug 7, 2025
• Terns Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Corporate Updates
  Aug 5, 2025
• Terns Pharmaceuticals CEO & Director Acquires 98% More Stock
  Jul 4, 2025
• Terns Pharmaceuticals Reports Positive Phase 1 Results for Oral Weight Loss Drug
  Jun 23, 2025
• Terns Pharmaceuticals Presents Positive Data from Phase 1 Study of TERN-601 Once-daily Oral GLP-1R Agonist for Treatment of Obesity at 85th Annual American Diabetes Association Scientific Sessions
  Jun 23, 2025
• Terns Pharmaceuticals to Participate in Upcoming June Investor Conferences
  May 29, 2025
• Terns Pharmaceuticals Selected for Oral Presentation at European Hematology Association Congress For Preclinical Data on Novel Allosteric BCR-ABL Inhibitor TERN-701
  May 14, 2025